Can you lower your PFAS levels? The experiment has not been run

The most common question people ask about PFAS is whether they can do anything about it. The honest answer, as of late August 2026, is that the study capable of answering it is at the protocol stage.

A paper published on 14 August sets out the design of an analysis intended to determine whether there is a causal relationship between PFAS and serum lipid levels, by emulating a target trial of a hypothetical PFAS-reduction intervention using observational data [s1]. Its opening premise is the state of the field: PFAS are associated with higher serum lipids, but primarily in cross-sectional studies, which limits causal inference [s1].

What the planned study would do

The hypothetical trial being emulated would enrol adults aged 20 and over without prior cardiovascular, kidney or liver disease, without diabetes, and not using related medications [s1]. Participants would be randomly assigned either to PFAS-reduction counselling or to no counselling, with adherence evaluated after 10 years and serum lipids assessed at a follow-up 10 years later [s1].

Because that trial has not been run, the researchers plan to emulate it using the Copenhagen City Heart Study, drawing on three successive clinical visits — baseline, follow-up, and outcome assessment — spaced 10 years apart [s1]. Intervention strategies would be defined by the reductions in PFAS concentrations actually observed between the baseline and follow-up visits, with serum lipids measured at the outcome visit and confounding handled by G-computation [s1].

Target trial emulation is a serious method, and the paper is explicit about what it is: an attempt to improve causal inference in environmental epidemiology, resting on an exchangeability assumption that has to be met by adjusting for baseline and time-varying confounders [s1]. It is not a randomised trial, and its authors do not present it as one. It also has no results yet — this is the protocol.

Why nobody has simply run the trial

Two obstacles, and both are structural.

The first is that individual exposure is largely not under individual control. A study of 40 Faroese homes estimated that indoor air and dust contributed roughly 0.2%, 2% and 20% of the European Food Safety Authority's tolerable weekly intake for 15-year-old children under low, intermediate and high exposure scenarios, against about 60% from average consumption of pilot whale [s2]. In eight primary schools in Porto, all PFAS classes showed indoor enrichment relative to outdoor air, and children had higher body-weight-normalised inhalation exposure than adults in the same rooms [s4]. A child's exposure at school is not something a household can change.

The second is timescale. PFAS persist in the body, which is why the Copenhagen design uses ten-year intervals [s1]. An intervention study with a short follow-up would be measuring noise.

What is known about modification, as opposed to reduction

One recent study looked at the adjacent question: not whether reducing exposure helps, but whether anything changes the strength of the association.

Among 192 propensity score-matched case-control pairs, researchers examined six serum PFAS against hyperlipidemia alongside a composite lifestyle score built from smoking, alcohol drinking, physical activity, body shape and diet [s3]. Among participants with an unhealthy lifestyle — a composite score of 2 or below, based on the population median — higher PFOA, PFHxS and PFNA were associated with significantly elevated odds of hyperlipidemia [s3]. For 6:2 Cl-PFESA, perfluorodecanoic acid and perfluoroundecanoic acid, associations were generally weaker among participants adhering to a relatively healthy lifestyle, supported by significant multiplicative interactions [s3].

The authors suggest lifestyle modification may serve as a potential public health strategy to reduce environmental metabolic hazards [s3]. That is a hypothesis from a subgroup analysis in 192 pairs, and it comes with a confounding problem: the lifestyle score includes diet and body shape [s3], both of which are related to PFAS exposure and to blood lipids independently. It is not evidence that changing habits offsets a chemical exposure, and it should not be read as such.

What the evidence does not support

It is worth stating the negative claims plainly, because this is a subject where confident advice circulates far ahead of data.

No study cited here shows that any behaviour change lowers serum PFAS. No study cited here shows that lowering serum PFAS improves any health outcome — that is precisely the question the Copenhagen protocol is designed to approach, and it has not yet reported [s1]. And none of these studies is a trial of anything.

What the exposure literature does establish is where the exposure comes from, which is a different and more tractable finding. In the Faroese case diet dominated, with indoor air and dust contributing a smaller but non-trivial share that rises as dietary sources decline [s2]. In the Porto schools, indoor air was enriched relative to outdoors and precursor compounds — not the regulated terminal acids — made up the majority of what was measured [s4].

What to watch

Three things would change the picture. Results from the Copenhagen emulation, which would be the first serious estimate of whether reduced exposure moves a clinical measure [s1]. National biomonitoring showing whether population serum concentrations are falling as production controls take effect. And exposure-source studies in ordinary residential and school settings outside the unusual populations that dominate the current literature [s2] [s4].

Until then, the accurate summary is that PFAS exposure is well characterised, the health associations are real but mostly cross-sectional, and the question of whether reducing exposure changes anything is open. This article makes no recommendation about diet, water treatment or consumer products, because the evidence to support one does not exist.

Sources

• [s1] Effects of PFAS Exposure Reduction on Serum Lipids in the Copenhagen City Heart Study: A Protocol for an Observational Cohort Study Emulating a Target Trial. Toxics, 14 August 2026. https://doi.org/10.3390/toxics14080722
• [s2] Contribution of Indoor Air and Dust to Children's Per- and Polyfluoroalkyl Substance Exposure in the Faroe Islands. Environmental Science & Technology, 30 July 2026. https://doi.org/10.1021/acs.est.6c02003
• [s3] Healthy lifestyle modifies the association between per- and polyfluoroalkyl substances and hyperlipidemia: A propensity score-matched case-control study. International Journal of Hygiene and Environmental Health, 3 August 2026. https://doi.org/10.1016/j.ijheh.2026.114880
• [s4] Per- and polyfluoroalkyl substances (PFAS) in Portuguese primary schools: Occurrence in air and implications for children's inhalation exposure. Environmental Research, 21 August 2026. https://doi.org/10.1016/j.envres.2026.125533